CBP-174
/ Suzhou Connect Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 30, 2022
"$CNTB Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study https://t.co/kx4YU9obH5"
(@stock_titan)
June 15, 2022
Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=72 | Completed | Sponsor: Connect Biopharma Australia Pty Ltd | Recruiting ➔ Completed
Trial completion
May 11, 2022
Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Connect Biopharma Australia Pty Ltd | Trial completion date: Sep 2022 ➔ Jun 2022
Trial completion date
1 to 3
Of
3
Go to page
1